Template:Propranolol: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) No edit summary |
Ahmed Zaghw (talk | contribs) No edit summary |
||
Line 25: | Line 25: | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Propranolol nonclinical toxicology|Nonclinical Toxicology]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Propranolol nonclinical toxicology|Nonclinical Toxicology]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Propranolol how supplied storage and handling|How Supplied/Storage and Handling]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Propranolol how supplied storage and handling|How Supplied/Storage and Handling]] |
Revision as of 23:55, 4 February 2014
Propranolol |
---|
Inderal LA®, InnoPran XL® FDA Package Insert |
Indications and Usage |
Dosage and Administration |
Contraindications |
Warnings and Precautions |
Adverse Reactions |
Drug Interactions |
Use in Specific Populations |
Overdosage |
Description |
Clinical Pharmacology |
Nonclinical Toxicology |
How Supplied/Storage and Handling |
Patient Counseling Information |
Labels and Packages |
Clinical Trials on Propranolol |
ClinicalTrials.gov |